Allogene Therapeutics Inc logo

Allogene Therapeutics Inc

7
NAS:ALLO (USA)  
$ 2.47 -0.05 (-1.98%) 10:08 PM EST
At Loss
P/B:
0.71
Market Cap:
$ 415.64M
Enterprise V:
$ 40.24M
Volume:
2.65M
Avg Vol (2M):
1.99M
Volume:
2.65M
At Loss
Avg Vol (2M):
1.99M

Business Description

Allogene Therapeutics Inc logo
Allogene Therapeutics Inc
NAICS : 325414 SIC : 2836
ISIN : US0197701065
Description
Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
Name Current Vs Industry Vs History
Cash-To-Debt 5.17
Equity-to-Asset 0.82
Debt-to-Equity 0.16
Debt-to-EBITDA -0.28
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -1.77
Distress
Grey
Safe
Beneish M-Score -3.45
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 40.14
9-Day RSI 42.26
14-Day RSI 42.89
6-1 Month Momentum % -50.69
12-1 Month Momentum % -68.15

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 12.58
Quick Ratio 12.58
Cash Ratio 12.37

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -5.1
Shareholder Yield % -2.14

Financials (Next Earnings Date:2024-02-28 Est.)

ALLO's 30-Y Financials
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:ALLO

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014

Allogene Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0.186
EPS (TTM) ($) -2.24
Beta 0.06
Volatility % 55.05
14-Day RSI 42.89
14-Day ATR ($) 0.252586
20-Day SMA ($) 2.61575
12-1 Month Momentum % -68.15
52-Week Range ($) 2.23 - 9.06
Shares Outstanding (Mil) 168.28

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Allogene Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Allogene Therapeutics Inc Stock Events

Event Date Price($)
No Event Data

Allogene Therapeutics Inc Frequently Asked Questions

What is Allogene Therapeutics Inc(ALLO)'s stock price today?
The current price of ALLO is $2.47. The 52 week high of ALLO is $9.06 and 52 week low is $2.23.
When is next earnings date of Allogene Therapeutics Inc(ALLO)?
The next earnings date of Allogene Therapeutics Inc(ALLO) is 2024-02-28 Est..
Does Allogene Therapeutics Inc(ALLO) pay dividends? If so, how much?
Allogene Therapeutics Inc(ALLO) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1